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Abstract
Introduction: Women with type 1 diabetes mellitus (T1DM) experience high prevalence of hyperandrogenic disorders. The aim of this 
study was to evaluate hormonal profile with respect to hyperandrogenic disorders in adolescents with T1DM. 
Material and methods: Forty seven adolescent girls with T1DM were evaluated and compared to 19 healthy and 21 non-diabetic girls 
with polycystic ovary syndrome (PCOS). In all subjects, basal and GnRH analogue stimulated androgens, gonadotropins and SHBG were 
measured and ultrasonography of ovaries was performed. 
Results: Girls with T1DM experienced first menses significantly later than healthy controls [13.1 (12.0–14.0) v. 12.0 (11.0–12.0) years, 
p = 0.02]. Nine (19.2%) of them fulfilled PCOS criteria (T1DM+PCOS). They had significantly mean HbA1c from the diagnosis of T1DM 
than T1DM girls with no PCOS [6.7 (6.6–7.2) v. 7.3(6.4–7.8)%, p = 0.049]. Hormonal profile, hirsutism score and ovarian volume did not 
differ significantly between the two groups. HbA1c at the study point and mean HbA1c for the last 12 months correlated negatively with 
SHBG level (r = –0.5, p = 0.006; r = –0.04, p = 0.02). T1DM+PCOS girls had significantly lower FAI [3.0 (2.6–4.3) v. 8.6 (6.5–10.8), p = 0.04] 
and ovarian volume than non-diabetic PCOS girls [4.6 (2.7–5.2) v. 7.4 (4.3–10.0) mL, p = 0.007]. 
Conclusions: Clinical symptoms of PCOS in adolescent girls with T1DM are milder than in non-diabetic peers, probably due to the pro-
tective role of higher SHBG resulting in lower free androgen level. (Endokrynol Pol 2013; 64 (2): 121–128)
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Streszczenie
Wstęp: U kobiet z cukrzycą typu 1 (T1DM) stwierdza się zwiększoną częstość występowania klinicznych i biochemicznych objawów 
hiperandrogenizmu. Celem pracy była ocena profilu hormonalnego oraz częstości występowania hiperandrogenizmu u dojrzewających 
dziewcząt z T1DM.
Materiał i metody: Do badania włączono 47 dziewcząt z T1DM oraz 19 zdrowych i 21 dziewcząt z zespołem policystycznych jajników 
(PCOS). U wszystkich dziewcząt dokonano oceny klinicznej i ultrasonograficznej oraz przeprowadzono badania hormonalne przed i po 
stymulacji analogiem GnRH.
Wyniki: U dziewcząt z T1DM pierwsza miesiączka występowała istotnie później aniżeli u zdrowych dziewcząt [13,1 (12,0–14,0) v. 12,0 
(11,0–12,0) lat, p = 0,02]. Dziewięć (19,2%) z nich spełniało kryteria rozpoznania PCOS (T1DM+PCOS). U dziewcząt z cukrzycą, u których 
zdiagnozowano PCOS, stwierdzono istotnie niższą średnią HbA1c od początku zachorowania na T1DM aniżeli u dziewcząt z T1DM bez 
PCOS [6,7 (6,6–7,2) v. 7,3 (6,4–7,8)%, p = 0,049]. Hirsutyzm, objętość jajników oraz profil hormonalny nie różniły się pomiędzy grupa-
mi. HbA1c oznaczona w momencie badań oraz średnia HbA1c z ostatniego roku korelowały negatywnie ze stężeniem SHBG (r = –0,5, 
p = 0,006; r = –0,04, p = 0,02). Dziewczęta T1DM+PCOS miały istotnie niższy indeks wolnych androgenów [3,0 (2,6–4,3) v. 8,6 (6,5–10,8), 
p = 0,04] i objętość jajnika aniżeli dziewczęta z PCOS nie chorujące na cukrzycę [4,6 (2,7–5,2) v. 7,4 (4,3–10,0) ml, p = 0,007]. 
Wnioski: Kliniczne objawy PCOS u dojrzewających dziewcząt z T1DM są łagodniejsze aniżeli u dojrzewających dziewcząt nie chorujących 
na cukrzycę. Może być to spowodowane protekcyjną rolą SHBG i mniejszą ilością wolnych androgenów. (Endokrynol Pol 2013; 64 (2): 121–128)
Słowa kluczowe: cukrzyca typu 1, zespół policystyczncych jajników, hiperandrogenizm, dojrzewające dziewczęta
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Introduction
Polycystic ovary syndrome (PCOS) is the commonest 
endocrine disorder in women of reproductive age. 
According to National Institute of Health (NIH) 1990 
criteria, it affects 6–8% and according to Rotterdam 
consensus about 12% of adult women [1]. PCOS is 
a heterogeneous condition, characterised by oligoovula-
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tion and clinical and/or biochemical hyperandrogenism, 
and is frequently associated with hyperinsulinaemia 
and insulin resistance. It has been suggested that hy-
perinsulinaemia may contribute to PCOS development 
by enhancing androgen production [2, 3]. 
Insulin receptors are present in many compart-
ments of the ovary including granulosa, thecal, and 
stromal cells [4, 5]. Moreover, insulin can also bind to 
the IGF-1 receptors in the female gonad which could 
mediate the effects of hyperinsulinaemia in the ovary 
[6]. In vitro and in vivo studies have shown that insu-
lin can act as co-gonadotropin and together with LH 
may stimulate androgens’ production in theca cells [7, 
8]. Insulin affects also other steroidogenic enzymes, 
stimulates synthesis of oestrogen and progesterone, 
activates IGF-1 system, enhances ovarian growth and 
cyst formation, stimulates theca cell proliferation, and 
influences ovulation [3].
Increased incidence of menstrual disturbances, 
hirsutism and PCOS have been reported in women 
with type 1 diabetes mellitus (T1DM) [9–11]. Some 
authors have suggested that this could be due to non-
physiologic insulin replacement therapy, leading to 
increased insulin level in systemic circulation. Under 
the physiological condition pancreas secretes insulin 
into the portal circulation. The main target organ of 
insulin action is the liver, where 50-70% of insulin is 
eliminated [12]. In diabetic patients, to deliver an ap-
propriate amount of insulin to the liver and achieve 
good metabolic control, supraphysiological doses of 
insulin are injected subcutaneously. Due mainly to co-
gonadotropin action, hyperinsulinaemia can therefore 
stimulate androgens synthesis in the ovaries, leading 
to PCOS development [13, 14]. 
Girls with T1DM have been found to have differ-
ent ovarian steroidogenic response to GnRH-analogue 
stimulation compared to healthy peers [15]. Some of 
them may develop hyperandrogenism, which may 
evolve towards PCOS in adulthood. However there is 
little data concerning the incidence of hyperandroge-
nism in this group of patients and it is not clear which 
factors related to T1DM can influence the ovarian 
steroidogenesis. 
The aim of our study was to evaluate the clinical 
characteristics and ultrasonography of the ovary as well 
as the hormonal profile of adolescent girls with T1DM 
with respect to their metabolic control and the type of 
insulin therapy and compare these results with nondia-
betic PCOS girls and healthy controls matched for age.
Material and methods
All the girls attending the diabetes clinic of the Paedi-
atric University Hospital of Silesia, Katowice, who had 
menstruated for at least one year, were consecutively in-
vited to participate in the study. Forty seven adolescent 
girls were finally recruited. They had been diagnosed 
with T1DM at least one year earlier. In all patients, 
T1DM diagnosis was confirmed (C-peptide level < 0.05 
nmol/L, presence of specific antibodies), and intensive 
insulin therapy was applied. Twenty seven (57%) girls 
were treated with intermediate (NPH) or long-acting 
insulin (glargine) and multiple daily injections (MDI) 
with at least three per day injections of rapid acting 
insulin analogues, and 20 (43%) girls — with continu-
ous subcutaneous insulin infusion (CSII) by means of 
an insulin pump. Twenty one adolescents with PCOS 
and 19 healthy, regularly menstruating adolescent girls 
with no clinical signs of hyperandrogenism, matched 
for chronological and gynaecological age, served as the 
control groups. The exclusion criteria were: honeymoon 
period, specific types of diabetes, type 2 diabetes mel-
litus, abnormal thyroid function, hyperprolactinaemia, 
congenital adrenal hyperplasia (based on basal 17-0H 
progesterone level > 3.0 ng/mL), use of medications 
known to influence sex steroids or sex hormone binding 
globuline (SHBG) in last three months, chronic systemic 
disease and malnutrition. All the girls participating in 
the study were Caucasians. The study was conducted 
according to the Helsinki declaration and approved by 
the Ethics Committee of the Medical University of Sile-
sia. Informed consent was obtained from each subject 
and parent/guardian.
In all participants, menstrual cycle pattern was 
evaluated and oligomenorrhoea was defined as men-
strual cycles longer than 45 days in the last six months. 
Weight was measured with Seca scale with a precision 
of 100g and height with Harpenden stadiometer to 0.1 
cm. BMI and BMI z-score were calculated. Hirsutism 
was evaluated by one of the two authors (A.Z. and A.G.) 
and diagnosed if the modified Ferriman-Gallwey score 
was ≥ 8. In each girl, a transabdominal pelvic ultrasound 
examination was performed by the same observer (A. 
D-C.) with 5 MHz convex transducer (Siemens Acuson 
Antares 5.0), and volume and structure of the ovaries 
were evaluated. Ovaries were considered polycystic 
(polycystic ovary morphology, PCOM) if 12 or more 
follicles 2–9 mm in diameter were present at least in 
one ovary and if increased ovarian volume (> 10 mL) 
occurred. In each subject with T1DM, detailed medical 
history was obtained, including age at the onset of T1DM, 
HbA1c records from the beginning of the disease, and 
daily insulin requirement (DIR) for the last three days, 
expressed as units per kilograms of body weight per day.
Basal plasma concentration of gonadotropins (LH, 
FSH), androstenedione (A), testosterone (T), 17-hy-
droxyprogesterone (17OHP), dehydroepiandrosterone 
sulfate (DHEAS), oestradiol (E2), SHBG, IGF-1 and HbA1c 
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were measured. Free androgen index (FAI = Tx100/ 
/SHBG) and LH/FSH ratio were calculated. All subjects 
underwent GnRH-analogue test with triptorelin (0.1 
mg) administered subcutaneously as previously de-
scribed [16]. Blood samples were collected four hours 
post stimulation for measurement of LH and FSH con-
centrations, and 24 hours post stimulation for 17OHP, 
A, DHEAS, T and E2 plasma level. All the tests were 
performed during the follicular phase of menstrual 
cycle (3–7 day of cycle). Biochemical hyperandroge-
naemia was defined if T level exceeded 58 ng/dL, A 
— 2.44 ng/mL and DHEAS — 248 mg/dL [17]. PCOS 
was diagnosed according to the Androgen Excess and 
PCOS Society criteria [18].
Serum levels of LH, FSH, T, DHEAS, E2, and IGF-1 
were measured using chemiluminescent immunoas-
say by Immulite 2000 analyser (DPC, USA), HbA1c was 
measured by high-performance liquid chromatography 
method, and SHBG was determined by immunoradio-
metric assay (Radim, Roma, Italy). 17OHP and A were 
measured by enzyme-linked immunosorbent assay 
(DRG Diagnostics GmbH, Germany).
Anthropometric data and hormonal results were 
compared using Statistica 8.0 PL. All values were ex-
pressed as mean ± standard deviation for normal or 
median (interquartile range) for skewed distribution. 
Correlation analysis was performed using Pearson’s 
correlation coefficient for normally distributed samples, 
and Spearman correlation coefficient for non-normally 
distributed data. Gamma correlation was used for non-
normal distributions with many tied ranks. Comparison 
between groups was performed using t-Student test for 
normally distributed data and Mann-Whitney U test 
for skewed distributions. Differences between the four 
groups (T1DM no PCOS, T1DM with PCOS, PCOS, and 
control) were assessed by one-way ANOVA or Kruskal-
Wallis test, followed by the least-significant difference 
(LSD) test for multiple comparisons when applicable. 
P value < 0.05 was considered statistically significant 
and 0.05 < p ≤ 0.1 was considered as a trend toward 
statistical significance.
Results
Clinical and hormonal characteristics of the girls with 
T1DM and healthy, regularly menstruating girls are 
shown in Table I. Girls with T1DM experienced first 
menses significantly later, therefore their gynaecologi-
cal age was shorter. Forty three (87.2%) diabetic girls 
experienced menarche after T1DM diagnosis, in three 
girls (6.4%) menarche and T1DM occurred at the same 
age, and in the other three (6.4%) T1DM was diagnosed 
after menarche. There were no significant differences in 
examined hormonal profile between girls with T1DM 
and healthy controls. The clinical manifestations of 
hyperandrogenism were found in 18 (36.7%) subjects 
— menstrual disturbances in 16 (32.6%) girls and/or 
hirsutism of 8 points in three (6.4%) girls. None of the 
girls presented with a hirsutism score above 8. PCOM 
on ultrasound was seen in 18 (38.3%) diabetic girls and 
hyperandrogenaemia was present in 21 (44.7%) girls. 
The hyperandrogenic disorders, defined as the pres-
ence of polycystic ovaries or hirsutism, were found in 
19 (40.4%) girls.
The criteria of PCOS diagnosis were fulfilled by 
nine (19.2%) diabetic girls (T1DM+PCOS) according 
to the Androgen Excess and PCOS Society {by one 
(2.1%) girl according to the NIH, and by 12 (25.5%) 
subjects by ESHRE/ASRM criteria [19]}. Three of the 
T1DM+PCOS girls had clinical manifestations of the 
syndrome (oligomenorrhoea and/or hirsutism) together 
with PCOM and/or hyperandrogenaemia and the other 
six — PCOM with hyperandrogenaemia only. 
There were no significant differences in the age of 
T1DM diagnosis, T1DM duration, HbA1c at the study 
point, mean HbA1c for the last 12 months and DIR per 
kg between diabetic girls with and without PCOS (Ta-
ble I). Although the mean HbA1c from the beginning 
of T1DM was higher in diabetic girls without PCOS 
than in T1DM + PCOS girls, there were no significant 
differences between the two groups with respect to 
hormones concentrations and FAI. 
When compared to non-diabetic girls with PCOS, 
girls with T1DM experienced less pronounced clinical 
manifestations of the syndrome (Table II). Their men-
strual cycle was significantly shorter. They also had 
significantly lower volume of left ovary and lower FAI. 
Basal and stimulated testosterone, DHEAS and andros-
tenedione concentrations were similar in both groups. 
There were also no differences in basal and stimulated 
other hormones levels between T1DM+PCOS girls 
and PCOS girls. 
Following the recommendations of ISPAD [20], we 
divided girls with T1DM into two groups — well con-
trolled (mean HbA1c level for the last 12 months < 7.5%, 
36 girls) and poorly controlled (mean HbA1c for the last 
12 months ≥ 7.5%, 12 girls) (Table III). The occurrence of 
PCOS components (menstrual disturbances, hirsutism, 
PCOM and/or hyperandrogenaemia) was similar in 
both groups [24 (68.6%) well controlled girls v. ten (83%) 
poorly controlled girls, p > 0.05]. Girls with well con-
trolled T1DM had significantly lower stimulated T level 
than girls with poorly controlled T1DM. IGF-1 as well 
as basal and stimulated 17OHP concentrations were 
significantly higher in well controlled girls. Girls with 
poor metabolic control had significantly higher BMI 
z-score. There was no significant difference between 
the two groups with respect to DIR per kg.
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HbA1c at the study point and mean HbA1c for the 
last 12 months correlated negatively with SHBG level 
(r = –0.5, p = 0.006; r = –0.04, p = 0.02). Mean HbA1c from 
the beginning of T1DM correlated negatively with basal 
and stimulated 17OHP level (r = –0.5, p = 0.002; r = –0.5, 
p = 0.002, respectively). There was a negative correlation of 
HbA1c at the study point with stimulated E2 concentration 
(r = –0.4; p = 0.006). T1DM duration correlated negatively 
with stimulated LH level (r = –0.3, p = 0.03), and stimu-
lated 17OHP concentration (r = –0.4; p = 0.02). Correlation 
between hyperandrogenic disturbances occurrence and 
DIR per kg, age at T1DM diagnosis, T1DM duration, mean 
HbA1c for the last 12 months and HbA1c at the study point 
were not statistically significant. 
To evaluate the influence of the type of therapy on 
hyperandrogenic disorders, we compared girls treated 
Table I. Clinical and hormonal characteristics of adolescent girls with type 1 diabetes mellitus (T1DM), adolescent girls with 
T1DM and no polycystic ovary syndrome (PCOS), adolescent girls with T1DM and PCOS, and control group of healthy girls 
Tabela I. Charakterystyka kliniczna i hormonalna dojrzewających dziewcząt z cukrzycą typu 1 (T1DM), dziewcząt z T1DM 
bez zespołu policystycznych jajników (PCOS), dziewcząt z T1DM i PCOS oraz zdrowych dziewcząt (grupa kontrolna)
Girls with T1DM  
(n = 47)
T1DM no PCOS  
(n = 38)
T1DM with PCOS  
(n = 9)
Control group  
(n = 19)
Chronological age (years) 15.9 (15.0–17.1) 15.8(15.0–16.8) 16.9 (15.7–17.2) 16.5 (15.2–17.3)
Age at menarche (years) 13.1 (12.0–14.0)1 13.0 (12.0–14.0)2 13.0 (13.0–14.0)3 12.0 (11.0–12.0)
Gynaecological age (months) 32.0 (20.0–42.0)4 29.0 (20.0–42.0) 36.0 (24.0–45.0)5 51.0 (38.0–65.0)
Cycle duration (days) 29.0 (28.0–36.0) 29.0 (28.0–36.0) 29.0 (27.0–34.0)
Age of T1DM diagnosis (years) 9.0 (6.5–11.7) 8.8 (6.3–11.8) 9.0 (7.0–10.0)
T1DM duration (years) 7.1 (5.0–9.0) 7.3 (4.9–9.0) 7.0 (6.0–8.7)
HbA1c at study point (%) 7.0 (6.2–7.6) 7.1 (6.2–7.8) 6.7 (6.6–7.2)
Mean HbA1c for last 12 months (%) 6.9 (6.4–7.5) 7.0 (6.4–8.0) 6.9 (6.4–7.0)
Mean HbA1c from the beginning of T1DM (%) 7.0 (6.3–7.5) 7.3 (6.4–7.8)6 6.7 (6.2–7.0)
Daily insulin requirement [U/kg/day] 0.8 (0.7–0.9) 0.8 (0.7–1.0) 0.8 (0.7–0.8)
BMI z-score 0.4 (0.0–0.9) 0.5 (0.1–1.0) 0.0 (–0.2–0.7) 0.5 (–0.1–2.0)
Ferriman-Gallwey score 1.0 (0.0–3.0) 0.5 (0.0–2.0) 2.0 (1.0–8.0) 2.0 (0.0–7.0)
Volume of the right ovary [mL] 5.0 (3.0–6.5) 4.9 (2.7–6.5) 5.6 (3.9–6.7) 5.0 (3.0–6.5)
Volume of the left ovary [mL] 4.1 (3.0–5.8) 4.1 (3.2–6.8) 4.6 (2.7–5.2) 3.8 (2.9–6.0)
Basal LH [IU/L] 3.1 (1.7–5.5) 2.8 (1.4–5.9) 3.8 (2.6–4.6) 3.5 (2.6–6.7)
Basal FSH [IU/L] 4.7 (3.6–5.8) 4.8 (3.6–5.8) 4.5 (4.1–4.9) 5.0 (3.8–6.5)
LH/FSH 0.6 (0.4–1.3) 0.5 (0.4–1.3) 0.9 (0.6–1.3) 0.9 (0.6–1.4)
Basal testosterone [ng/dL] 35.0 (21.7–52.8) 34.5 (21.7–49.8) 54.7 (27.0–57.3) 35.5 (21.7–52.9)
Stimulated testosterone [ng/dL] 49.3 (33.4–71.8) 45.2 (30.8–69.8) 60.9 (47.4–73.8) 49.8 (38.3–68.4)
Basal androstenedione [nmol/L] 8.1 (5.2–9.7) 7.7 (51–8.7) 9.6 (8.4–14.3) 6.7 (5.3–8.8)
Stimulated androstendione [nmol/L] 8.7 (7.3–10.4) 8.6 (6.5–9.9) 10.4 (9.8–15.4) 8.6 (6.9–11.5)
Basal DHEAS [µmol/L] 4.0 (2.9–6.0) 3.7 (2.5–5.4) 5.4 (3.3–7.1) 5.6 (4.8–6.3)
Stimulated DHEAS [µmol/L] 4.7 (3.5–6.5) 4.3 (3.0–6.2) 7.9 (5.0–8.3) 6.3 (4.7–8.0)
Basal 17OHP [nmol/L] 3.3 (2.4–4.2) 3.3 (2.5–4.0) 4.1 (2.8–4.3) 3.1 (2.1–4.2)
Stimulated 17OHP [nmol/L] 7.6 (4.8–9.7) 7.2 (4.5–9.7) 7.9 (6.4–11.4) 5.7 (4.9–8.2)
Basal oestradiol [pmol/L] 114.0 (85.9–155.0) 114.0 (80.0–155.0) 117.5 (88.5–149.0) 113.0 (82.2–175.0)
Stimulated oestradiol [pmol/L] 592.0 (396.0–885.0) 580.5 (437.0–804.0) 830.0 (364.0–896.0) 516.1 (328.0–742.0)
SHBG [nmol/L] 43.1 (33.1–64.4) 43.8 (37.6–65.6) 40.1 (30.1–59.8) 25.4 (18.8–45.2)
FAI 2.8 (1.8–3.4) 2.6 (1.7–3.4) 3.0 (2.6–4.3) 4.0 (2.8–7.0)
IGF-1 [µg/L] 302.0 (236.0–377.0) 301.0 (235.0–377.0) 304.5 (293.0–375.0) 292.0 (247.0–405.0) 
Values are median (interquartile range). SHBG — sex hormone binding globulin, FAI — free androgen index; 1Girls with T1DM v. control group p = 0.02; 2Girls with 
T1DM no PCOS v. control group p = 0.008; 3Girls with T1DM with PCOS v. control group p = 0.04; 4Girls with T1DM v. control group p = 0.001; 5Girls with T1DM with 
PCOS v. control group p = 0.005; 6Girls with T1DM no PCOS v. T1DM with PCOS p = 0.05
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with CSII to girls with MDI. PCOS occurrence as well 
as PCOS components incidence were similar in both 
groups [five (25%) girls v. four (15%) girls, p > 0.05; 15 
(75%) girls v. 19 (70.4%) girls, p > 0.05, respectively]. 
There were no significant differences between the two 
subgroups with respect to ovarian volume and hormo-
nal profile. Only SHBG level was significantly higher 
in the CSII group than in the MDI group (54.6 ± 17.8 
nmol/L v. 40.1 ± 17.9 nmol/L, p = 0.02).
Discussion
Although in women with T1DM, increased prevalence 
of hyperandrogenic disorders such as PCOS and hir-
sutism has been described, the occurrence of hyper-
androgenism in adolescents with T1DM has not been 
extensively evaluated. Our study results demonstrate 
that hormonal profile and clinical manifestations of hy-
perandrogenaemia in girls with T1DM are significantly 
different from adolescent girls with PCOS alone. 
There is no published epidemiological data on the 
prevalence of PCOS in adolescent girls with T1DM to 
compare to the results of our study. The hyperandro-
genic disorders, defined as the presence of polycystic 
ovaries or hirsutism, were found in 40.4% of girls 
with T1DM and the prevalence of PCOS in our group 
may seem high as 19.2% of them fulfilled the criteria 
of the syndrome. Nevertheless, this prevalence was 
much lower than in adult women, as Codner et al., 
using ESHRE/ASRM criteria, found PCOS in 40.5% of 
diabetic women [9]. In the study of Escobar-Morreale 
et al. [10], PCOS was present in 18.8% of diabetic 
subjects, and hyperandrogenic disorders were found 
in almost 39%. However, the data from the study of 
Table II. Clinical and hormonal characteristics of adolescent girls with type 1 diabetes mellitus (T1DM) with polycystic ovary 
syndrome (PCOS) and non-diabetic girls with PCOS (control group)
Tabela II. Charakterystyka kliniczna i hormonalna dojrzewających dziewcząt z cukrzycą typu 1 (T1DM) i zespołem 
policystycznych jajników (PCOS) oraz dziewcząt bez T1DM z rozpoznanym PCOS (grupa kontrolna z PCOS)
T1DM with PCOS (n = 9) Control group with PCOS (n = 21)
Chronological age (years) 16.9 (15.7–17.2) 16.3 (15.5–17.3)
Age at menarche (years) 13.0 (13.0–14.0) 12.0 (12.0–13.0)
Gynaecological age (months) 36.0 (24.0–45.0) 48.0 (33.5–57.0)1
Cycle duration (days) 29.0 (27.0–34.0) 57.5 (34.6–92.6)2
BMI z-score 0.0 (–0.2–0.7) 1.1 (0.1–1.7)
Ferriman-Gallwey score 2.0 (1.0–8.0) 11.0 (3.0–13.0)
Volume of the right ovary [mL] 5.6 (3.9–6.7) 7.7 (6.0–9.0)
Volume of the left ovary [mL] 4.6 (2.7–5.2) 7.4 (4.3–10.0)3
Basal LH [IU/L] 3.8 (2.6–4.6) 6.2 (3.5–10.4)
Basal FSH [IU/L] 4.5 (4.1–4.9) 4.9 (4.1–6.6)
LH/FSH 0.9 (0.6–1.3) 1.4 (0.8–1.8)
Basal testosterone [ng/dL] 54.7 (27.0–57.3) 62.5 (37.5–74.7)
Stimulated testosterone [ng/dL] 60.9 (47.4–73.8) 73.9 (47.6–103.0)
Basal androstenedione [nmol/L] 9.6 (8.4–14.3) 10.4 (6.1–12.4)
Stimulated androstenedione [nmol/L] 10.4 (9.8–15.4) 12.3 (9.1–15.7)
Basal DHEAS [µmol/L] 5.4 (3.3–7.1) 7.3 (5.8–8.1)
Stimulated DHEAS [µmol/L] 7.9 (5.0–8.3) 8.6 (6.0–10.3)
Basal 17OHP [nmol/L] 4.1 (2.8–4.2) 5.2 (4.1–6.6)
Stimulated 17OHP [nmol/L] 7.9 (6.4–11.4) 9.9 (6.95–12.0)
Basal oestradiol [pmol/L] 117.5 (88.5–149.0) 111.0 (84.4–160.0)
Stimulated oestradiol [pmol/L] 830.0 (364.0–896.0) 738.0 (492.0–958.0)
SHBG [nmol/L] 40.1 (30.1–59.8) 22.8 (15.1–28.4)
FAI 3.0 (2.6–4.3) 8.6 (6.5–10.8)4
IGF-1 [µg/L] 304.5 (293.0–375.0) 297.0 (243.0–481.0)
Values are median (interquartile range); SHBG — sex hormone binding globulin; FAI — free androgen index; 1p = 0.01; 2p = 0.005; 3p = 0.007; 4p = 0.04
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Escobar-Morreale et al. [10] are not comparable to our 
group because of the different age frames of the sub-
jects and various criteria applied by the authors. We 
used the Androgen Excess and PCOS Society criteria 
that are more liberal in PCOS diagnosis than the NIH 
criteria used by Escobar-Morreale et al. [10]. If NIH 
criteria had been used by us, the frequency of PCOS 
in our group of adolescent girls would have been 2.1% 
only, so even lower than the prevalence observed by 
Codner et al. in adult women with T1DM, which was 
11.9% [9] and similar to that reported in the general 
population [1]. The lower incidence of PCOS in our 
group of adolescent girls than in the Codner et al. [9] 
and Escobar-Morreale el al. [10] studies could be ex-
plained by the shorter time of exposure to exogenous 
insulin due to shorter diabetes duration, as well as 
younger gynaecological age. 
The prevalence of hirsutism was much lower in our 
patients than in other studies [9,10]. Escobar-Morreale 
et al. [10] found hirsutism ≥ 8 score in 20% of regularly 
menstruating diabetic women, while Codner et al. [9] 
described hirsutism of low score in 28% of patients. In 
our study, only three (6.4%) girls had hirsutism scoring 
8 on the Ferriman-Gallway scale and one of them also 
experienced menstrual disturbances. Lower hirsutism 
occurrence in adolescent diabetic girls compared to 
Table III. Clinical and hormonal characteristics of adolescent diabetic girls with well controlled (mean HbA1c level from the 
last 12 months < 7.5 %) and poorly controlled type 1 diabetes mellitus (mean HbA1c level from the last 12 months ≥ 7.5%)
Tabela III. Charakterystyka kliniczna i hormonalna dojrzewających dziewcząt z dobrze wyrównaną (średnia HbA1c z ostatnich 
12 miesięcy < 7,5%) i źle wyrównaną cukrzycą typu 1 (średnia HbA1c z ostatnich 12 miesięcy ≥ 7,5%)
Well controlled (n = 35) Poorly controlled (n = 12)
Chronological age (years) 15.9 ± 1.4 15.8 ± 1.4
Age at first menses (years) 13.0 (12.0–14.0) 13.0 (12.0–14.0)
Age at T1DM onset (years) 9.0 ± 3.5 7.4 ± 3.8
T1DM duration (years) 6.9 ± 3.2 8.2 ± 4.2
HbA1c at the study point (%) 6.8 ± 0.8 10.0 ± 2.8
1
Mean HbA1c for last 12 months (%) 6.7 ± 0.6 9.5 ± 1.3
1
Mean HbA1c for T1DM’s span (%) 6.7 ± 0.6 8.6 ± 1.2
1
Daily insulin requirement [U/kg/day] 0.8 (0.7–0.9) 0.8 (0.8–1.0)
BMI z-score 0.4 ± 0.5 0.8 ± 0.73
Right ovary volume [mL] 5.3 ± 2.5 4.4 ± 2.2
Left ovary volume [mL] 4.5 ± 1.9 5.0 ± 3.2
Basal LH [IU/L] 3.4 (1.7–5.9) 2.1 (1.5–4.8)
Basal FSH [IU/L] 4.5 (3.6–5.5) 5.2 (3.7–5.9)
LH/FSH 1.0 (0.4–1.3) 0.5 (0.4–1.2)
Basal testosterone [ng/dL] 34.8 (20.0–52.8) 39.6 (22.6–60.2)
Stimulated testosterone [ng/dL] 48.8 ± 20.4 70.9 ± 44.44
Basal androstenedione [nmol/L] 8.8 (5.9–9.7) 7.7 (4.9–9.1)
Stimulated androstenedione [nmol/L] 8.9 (7.3–10.6) 8.4 (5.9–9.8)
Basal 17OH-progesterone [nmol/L] 3.5 (2.6–4.6) 2.7 (1.8–3.3)3
Stimulated 17OH-progesterone [ng/mL] 7.9 (5.8–10.3) 5.2 (3.9–7.6)5
Basal DHEAS [mmol/L] 4.3 ± 1.8 4.0 ± 1.4
Stimulated DHEAS [mmol/L] 5.3 ± 2.0 4.3 ± 1.4
Basal oestradiol [pmol/L] 110.5 (85.9–158.0) 117.0 (84.5–139.5)
Stimulated oestradiol [pmol/L] 617.0 (477.0–991.0) 332.3 (207.0–558.5)
SHBG [nmol/L] 49.7 ± 19.2 37.6 ± 16.6
FAI 2.7 (1.8–3.1) 2.9 (2.1-3.8)
IGF-1 [mg/L] 329.7 ± 84.9 235.6 ± 74.82
Values are mean ± standard deviation for normal or median (interquartile range) for skewed distribution. SHBG — sex hormone binding globulin,  
FAI — free androgen index. Well-controlled v. poorly-controlled: 1p ≤ 0.001; 2p = 0.003; 3p = 0.02; 4p = 0.03; 5p = 0.04
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adult women could be associated with younger gy-
naecological age of our patients and shorter time of 
excessive hair growth stimulated by hyperandroge-
naemia. Other authors also suggest that milder signs 
of hyperandrogenism in adolescent girls with T1DM 
are due to the fact that the clinical and laboratory find-
ings of hyperandrogenaemia evolve slowly during the 
second decade of life [9,13]. Some of them even applied 
lower scoring for hirsutism diagnosed in girls than in 
adult women [15].
It may also seem that diabetic women experience 
a milder form of PCOS with scarce clinical features, 
the main manifestation being biochemical hyperan-
drogenaemia and PCOM [14]. In our study, clinical 
manifestations of the syndrome in diabetic girls were 
much less pronounced than in non diabetic adolescents 
with PCOS. This could be explained by the fact that the 
nonphysiological, subcutaneous way of insulin admin-
istration results in decreased insulin amount acting in 
the liver, leading to higher SHBG production and lower 
FAI. Only three out of nine girls with T1DM and PCOS 
had clinical manifestations of hyperandogenism, while 
the other six had an increased level of androgens and 
PCOM. Although these six girls fulfilled the criteria of 
PCOS, both ESHRE/ASRM and the Androgen Excess 
and PCOS Society [18,19], they had no clinical presen-
tation of the syndrome. A diagnosis of PCOS should 
therefore be made with caution, especially given that 
PCOM seems to be a physiologic condition during early 
adolescence [21].
It has been suggested that the pathogenesis of 
hyperandrogenism in women with T1DM and PCOS 
is different than in non diabetic women with PCOS 
and that insulin replacement therapy could be crucial 
[22]. Escobar-Morreale et al. [10] as well as Codner 
et al. [9] did not find any predisposing factors of 
hyperandrogenic disorders among clinical variables 
such as duration of T1DM, age of onset or the type of 
therapy. In our study we also did not find such cor-
relations or significant differences. However, in girls 
with poor metabolic control we found significantly 
higher stimulated testosterone level. Some association 
between hormones concentrations and mean HbA1c 
and T1DM duration were also present in our group of 
patients, not reported before by other authors. Nega-
tive correlation between T1DM duration and basal 
LH level and between HbA1c and stimulated E2 as well 
as SHBG concentrations can reflect the influence of 
metabolic control on ovarian and liver function. Sur-
prisingly, in girls with lower mean HbA1c for the last 
12 months and from the beginning of T1DM, higher 
concentrations of 17OHP were found. We suggest 
that the lower HbA1c could result from higher doses 
of insulin used for treatment that can be responsible 
for higher 17OHP level. Another explanation of this 
state could be just the stronger biological activity of 
insulin, manifested as better hypoglycaemic effect, 
better metabolic control but also excessive reaction of 
ovaries. In addition, higher IGF-1 concentration in girls 
with mean HbA1c for the last 12 months below 7.5% 
could be a co-factor increasing, together with insulin, 
production of 17OHP [3]. 
Therefore, both good and poor metabolic control 
could be possible reasons for hormonal disturbances 
associated with systemic hyperinsulinaemia.
Codner et al. [9] suggested that intensive insulin 
treatment may be a predisposing factor for PCOS and 
PCOM. However, their study was conducted on women 
over 20 years of age and subjects with intensive insulin 
treatment were compared to those on conventional 
therapy (< 3 insulin injections per day). In our study, 
in which we compared hyperandrogenism in girls 
with intensive therapy — MDI and CSII, hormonal 
profile was the same in two types of insulin therapy, 
although SHBG level was significantly higher in girls 
treated with CSII. 
Our data did not show the influence of obesity on 
the development of PCOS, as apart from the group 
with poor metabolic control, in which BMI z-score was 
significantly higher, all the other comparative groups 
did not differ in BMI z-score value.
Finally, we found that girls with T1DM experienced 
menarche significantly later than healthy girls. It has 
been reported that delay of menarche in diabetic girls 
could be associated with poor metabolic control, lower 
BMI, prepubertal onset of diabetes and longer duration 
of the disease [14]. We did not find any relationship 
of late menarche with HbA1c, T1DM duration, age of 
onset of diabetes, or BMI z-score. Rohrer et al. [23] sug-
gested that the cause of the delay in menarcheal age in 
T1DM girls may lie in the hypothalamic–pituitary level, 
especially in decreased LH secretion. In our study, LH 
levels as well as LH/FSH ratio in diabetic girls were not 
significantly lower then in healthy controls, which does 
not support that hypothesis.
Our study limitation was a heterogeneous duration 
of diabetes in the study group; however, the difference 
between girls with and without PCOS was statistically 
not significant. The other weak point was the relatively 
short gynaecological age of our patients. On the other 
hand, the aim of the study was to evaluate girls as young 
as possible to find out at what age they may start to 
develop hyperandrogenaemia.
We conclude that the frequency of the clinical 
features of PCOS and hyperandrogenaemia in adoles-
cent girls with T1DM seems to be lower than in adult 
diabetic women. The clinical manifestations of PCOS 
in these girls are mild. PCOS components occurrence 
128
PR
A
C
E 
O
RY
G
IN
A
LN
E
Hyperandrogenism in girls with T1DM  Agnieszka Zachurzok et al.
is independent of the type of insulin therapy, but poor 
metabolic control may decrease the protective role of 
SHBG. 
The results of our study suggest a different patho-
physiology of hyperandrogenism in adolescent girls 
with T1DM than in their peers with PCOS only. 
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